11/12
08:00 am
klrs
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
Low
Report
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
11/3
09:03 am
klrs
Kalaris Therapeutics (NASDAQ:KLRS) is now covered by analysts at Citizens Jmp. They set a "mkt outperform" rating and a $20.00 price target on the stock.
Medium
Report
Kalaris Therapeutics (NASDAQ:KLRS) is now covered by analysts at Citizens Jmp. They set a "mkt outperform" rating and a $20.00 price target on the stock.
11/3
07:30 am
klrs
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer
Low
Report
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer
11/3
05:02 am
klrs
Kalaris Therapeutics (NASDAQ:KLRS) is now covered by analysts at Citigroup Inc.. They set an "outperform" rating on the stock.
Low
Report
Kalaris Therapeutics (NASDAQ:KLRS) is now covered by analysts at Citigroup Inc.. They set an "outperform" rating on the stock.
10/30
08:00 am
klrs
Kalaris to Present at Stifel 2025 Annual Healthcare Conference
Low
Report
Kalaris to Present at Stifel 2025 Annual Healthcare Conference
10/4
12:06 am
klrs
Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by analysts at
Wall Stre
High
Report
Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by analysts at
Wall Stre
9/15
03:26 pm
klrs
UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
Low
Report
UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
9/15
08:00 am
klrs
Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
Medium
Report
Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration